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Background: One year results of ORAR III trial previously published showed similar safety and efficacy results with lower costs comparing oral 
treatment with sirolimus plus bare metal stent (OR) vs. drug eluting stents (DES) to prevent restenosis (NCT00552669).
Methods: From January 2006 to September 2007 in 3 hospitals in Buenos Aires, Argentina, 200 patients (pts) were randomized either to OR 
(n=100) or DES (n=100) with the primary objective of comparing clinical efficacy and safety of OR vs DES treatments for denovo coronary lesions 
evaluated by the composite of death, myocardial infarction (MI) and stroke; Target Vessel Failure (TVF) defined as cardiac death, MI and Target 
Vessel Revascularization (TVR) and TVR alone at 3 years of follow up. OR was given as a bolus of 10 mg the day before PCI followed by 3 mg/daily 
during the following 13 days. DES group received clopidogrel for at least one year and OR group for a month. DES used in the trial were Taxus, Boston 
Scientific (60%), Cypher, Johnson & Johnson (6%) and Endeavor, Medtronic (34%). Exclusion criteria were MI in the last 24 hours, in stent restenosis 
and previous PCI in the last six months.
Results: Baseline demographic, clinical and angiographic characteristics were similar. 1.6 +/- 0.7 vs 1.7 +/- 0.8 (p=0.3) lesions per pt were 
treated in OR vs DES respectively, and 171 stents in OR vs 176 in DES groups were deployed (p=0.9). Multiple vessel disease was present in 
48% of OR and 51% of DES (p=0.9). 3 years clinical follow up was accomplished in 99% of all pts. In DES group 55% of pts were still receiving 
thyenopiridines vs 23% of OR. Overall death was 5% vs 11% in OR vs DES respectively (0.11) and cardiac death was 2% vs 5% in OR vs DES 
respectively.(p=0.44). Composite of death, MI and stroke was 11.0% in OR group vs. 20.0% in DES, p=0.07; TVF was 25.0% in OR vs 32.0% in DES, 
p=0.27 and TVR was 14.5 % in OR group vs 17.6% in DES group, p=0.50.
Conclusions: 3 years follow up of this randomized trial, demonstrated non significant differences in safety and efficacy outcome in both treatment 
strategies. However, DES group showed a trend to high rate in hard cardiac events.
